⌘K

16:21:54·48d

SECFilingvia Quantisnow

SEC Form 144 filed by Adaptive Biotechnologies Corporation

ByQuantisnow·Wall Street's wire, on your screen.

ADPT· Adaptive Biotechnologies Corporation

Health Care

Original source

Quantisnowquantisnow.com

Quantisnow streams SEC filings, FDA approvals, analyst ratings, insider trades, and press releases to retail investors in real time. This insight was curated and delivered from the Quantisnow live feed.

Companies

ADPT
Adaptive Biotechnologies Corporation
Health Care

Recent analyst ratings

Dec 2UpdateMorgan Stanley$21.00
Sep 30UpdateGuggenheim$20.00
Jun 18UpdateCraig Hallum$15.00
Mar 21UpdateGoldman$9.00
Jul 5UpdateJP Morgan$15.00
Jan 5UpdateScotiabank$15.00

Related

INSIDER4d
President and COO Rubinstein Julie exercised 44,166 shares at a strike of $8.46 and sold $798,423 worth of shares (57,180 units at $13.96) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 382,132 units (SEC Form 4)
SEC4d
SEC Form DEFA14A filed by Adaptive Biotechnologies Corporation
SEC4d
SEC Form DEF 14A filed by Adaptive Biotechnologies Corporation
INSIDER7d
SEC Form 4 filed by Rubinstein Julie
INSIDER12d
SEC Form 4 filed by Rubinstein Julie
PR13d
Adaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 2026
INSIDER15d
SEC Form 4 filed by Rubinstein Julie
INSIDER18d
SEC Form 4 filed by Lo Francis

SEC Form 144 filed by Adaptive Biotechnologies Corporation | Quantisnow